Pralsetinib as neoadjuvant therapy for RET-Altered differentiated thyroid cancer: Two case reports

被引：0
|
作者：
Huang, Nai-Si [1 ,2 ]
Chen, Jia-Ying [1 ,2 ]
Meng, Yan [3 ]
Li, Qiu-Li [4 ,5 ]
Ji, Qing-Hai [1 ,2 ]
Wang, Yu [1 ,2 ]
机构：
[1] Fudan Univ, Dept Head & Neck Surg, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China
[3] Hainan Canc Hosp, Dept Oncol, Haikou, Peoples R China
[4] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China
[5] Sun Yat Sen Univ, Dept Head & Neck Surg, Canc Ctr, Guangzhou 510060, Peoples R China
来源：
ORAL ONCOLOGY | 2024年 / 159卷
关键词：
Differentiated thyroid carcinoma; Neoadjuvant therapy; Pralsetinib; Papillary thyroid carcinoma; RET-fusion; DOUBLE-BLIND; MANAGEMENT;
D O I：
10.1016/j.oraloncology.2024.107014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: 5-10% of thyroid cancers are at locally advanced stage. Neoadjuvant targeted therapy will likely create surgical opportunities for these patients with unresectable or borderline resectable tumors. Pralsetinib, a RET inhibitor, has been approved for advanced or metastatic RET-altered thyroid cancer. However, there is no evidence on the efficacy of pralsetinib as neoadjuvant therapy in locally advanced RET-altered thyroid cancer. Case report: Two patients with locally advanced pappilary thyroid carcinoma (PTC) were treated with pralsetinib (400 mg daily) to reduce tumor size and increase the chance of R0 resection. Both PTCs, characterized by RETfusion, underwent successful R0 resection without major surgical complications after 4-months neoadjuvant pralsetinib. Conclusion: There is a potential for pralsetinib as a neoadjuvant treatment in PTC with RET-fusion.
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Drug approval: Selpercatinib and pralsetinib - RET-altered thyroid cancer
    Courtier, Baudouin
    Hadoux, Julien
    [J]. BULLETIN DU CANCER, 2021, 108 (11) : 989 - 991
  • [2] Updated ARROW data: Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC)
    Hu, M. I.
    Subbiah, V.
    Mansfield, A. S.
    Taylor, M.
    Schuler, M. H. H.
    Zhu, V.
    Hadoux, J.
    Curigliano, G.
    Wirth, L. J.
    Garralda, E.
    Adkins, D. R.
    Godbert, Y.
    Ahn, M-J.
    Cassier, P. A.
    Cho, B. C.
    Lin, C-C.
    Barata, T.
    Zalutskaya, A.
    Scalori, A.
    Brose, M. S.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1298 - S1299
  • [3] Exposure-Response Relationships for Pralsetinib in Patients with RET-Altered Thyroid Cancer or RET Fusion-Positive Nonsmall Cell Lung Cancer
    Kassir, Nastya
    Mcdougall, David
    Kuruvilla, Denison
    Kim, Sean
    Kumar, Shaun
    Rahman, Ahmadur
    Ruf, Thorsten
    Cheeti, Sravanthi
    Ankrom, Wendy
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (06): : 685 - 696
  • [4] RET kinase inhibitors for RET-altered thyroid cancers
    Vodopivec, Danica M.
    Hu, Mimi I.
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [5] Precision therapy for RET-altered cancers with RET inhibitors
    Thein, Kyaw Z.
    Velcheti, Vamsidhar
    Mooers, Blaine H. M.
    Wu, Jie
    Subbiah, Vivek
    [J]. TRENDS IN CANCER, 2021, 7 (12) : 1074 - 1088
  • [6] Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC): Updated data from the ARROW trial.
    Mansfield, Aaron Scott
    Subbiah, Vivek
    Schuler, Martin H.
    Zhu, Viola Weijia
    Hadoux, Julien
    Brose, Marcia S.
    Curigliano, Giuseppe
    Wirth, Lori J.
    Garralda, Elena
    Adkins, Douglas
    Godbert, Yann
    Ahn, Myung-Ju
    Cassier, Philippe Alexandre
    Cho, Byoung Chul
    Lin, Chia-Chi
    Zhang, Hui
    Zalutskaya, Alena
    Barata, Teresa
    Scalori, Astrid
    Taylor, Matthew H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Drug approval: Selpercatinib and pralsetinib - RET-altered non-small cell lung cancer
    Courtier, Baudouin
    Pierret, Thomas
    [J]. BULLETIN DU CANCER, 2021, 108 (06) : 562 - 563
  • [8] Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
    Wirth, L. J.
    Sherman, E.
    Robinson, B.
    Solomon, B.
    Kang, H.
    Lorch, J.
    Worden, F.
    Brose, M.
    Patel, J.
    Leboulleux, S.
    Godbert, Y.
    Barlesi, F.
    Morris, J. C.
    Owonikoko, T. K.
    Tan, D. S. W.
    Gautschi, O.
    Weiss, J.
    de la Fouchardiere, C.
    Burkard, M. E.
    Laskin, J.
    Taylor, M. H.
    Kroiss, M.
    Medioni, J.
    Goldman, J. W.
    Bauer, T. M.
    Levy, B.
    Zhu, V. W.
    Lakhani, N.
    Moreno, V.
    Ebata, K.
    Nguyen, M.
    Heirich, D.
    Zhu, E. Y.
    Huang, X.
    Yang, L.
    Kherani, J.
    Rothenberg, S. M.
    Drilon, A.
    Subbiah, V.
    Shah, M. H.
    Cabanillas, M. E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (09): : 825 - 835
  • [9] Erectile Dysfunction in Patients Treated with Selpercatinib for RET-Altered Thyroid Cancer
    Matrone, Antonio
    Kroiss, Matthias
    Gild, Matti L.
    Hamidi, Sarah
    Sayehli, Cyrus Michael
    Siddal, Rhonda
    Gambale, Carla
    Prete, Alessandro
    Hu, Mimi I.
    Robinson, Bruce G.
    Elisei, Rossella
    [J]. THYROID, 2024,
  • [10] Selpercatinib (LOXO-292) in patients (pts) with RET-altered thyroid cancer
    Wirth, Lori J.
    Sherman, Eric J.
    Robinson, Bruce
    Solomon, Benjamin
    Kang, Hyunseok
    Lorch, Jochen H.
    Worden, Francis
    Brose, Marcia S.
    Leboulleux, Sophie
    Godbert, Yann
    Meurer, Marie
    Morris, John
    Owonikoko, Taofeek K.
    Tan, Daniel Shao-Weng
    Gautschi, Oliver
    Patel, Jyoti
    Yang, Luxi
    Kherani, Jennifer
    Cabanillas, Maria E.
    Shah, Manisha H.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S289 - S289
12345